NeuWave Medical is a Madison, Wisconsin-based medical device company that develops an intelligent ablation system for the ablation of soft-tissue lesions. Its platform is indicated for primary and metastatic lesions in the lung, liver and kidney. The system is currently being used by physicians in more than half of the top cancer institutions in the U.S. NeuWave is led by CEO Dan Sullivan and maintains a satellite office in Minneapolis, Minnesota. The company intends to use recent funding to expand commercialization efforts and to further develop its platform. NeuWave Medical develops and commercializes microwave and other energy-based soft tissue ablation devices, including the market-leading Certus 140 thermal ablation system. The company is headquartered in Madison, WI and was founded by engineers and physician-scientists who design clinically relevant, minimally invasive solutions. During the initial eighteen months of commercial availability, the Certus 140 has been used to treat over 1,500 patients at ninety leading healthcare institutions. NeuWave’s stated plans for the financing include furthering commercial success of the Certus 140 and continuing development of novel interventional and surgical tools. The company announced a $14 million Series B financing to support these efforts. Leadership emphasizes delivering innovative technology that enables improved patient care and positive healthcare economics for hospitals and systems.

Total raised

$39M

Funding rounds

2

Latest round

Series C

Latest activity

May 2015